BMS-794833 is primarily investigated for its potential in cancer therapy due to its role as a multi-kinase inhibitor. It targets specific kinases involved in tumor growth and angiogenesis, making it a candidate for treating various cancers, particularly those resistant to standard therapies. Research focuses on its ability to inhibit MET and VEGFR2 kinases, which play critical roles in pathways driving cancer progression and metastasis. Additionally, it is explored for its synergistic effects when combined with other anticancer agents, potentially enhancing treatment efficacy. Its application extends to preclinical studies aiming to understand its pharmacokinetics, safety profile, and therapeutic potential in oncology.